Tough Payor Policies Hamper Ryoncil Access

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawCassandra Rush, PharmDRemestemcel-L-rknd (Ryoncil, Mesoblast), the first-ever mesenchymal stromal cell therapy, is the only FDA-approved treatment for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children under 12 years of age. But it comes with some clear financial hurdles.The drug costs approximately $1.94 million for an average 10-dose course, based on its wholesale acquisition cost of $